Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.38 |
| ▸ | RELA | Q04206 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27513000 | 0.78 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2HSD17B10HDAC4 | |
| SCHEMBL12499609 | 0.77 | HDAC4 (0.40) | NPC1RAB9ASMN1; SMN2HSD17B10HDAC4 | |
| SCHEMBL533702 | 0.77 | HDAC4 (0.40) | NPC1RAB9ASMN1; SMN2HSD17B10HDAC4 | |
| SCHEMBL534160 | 0.77 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2HSD17B10NFKB1 | |
| SCHEMBL13364715 | 0.76 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2HSD17B10HDAC4 | |
| SCHEMBL2440707 | 0.74 | KDM4E (0.42) | NPC1RAB9ASMN1; SMN2HSD17B10NFKB1 | |
| SCHEMBL2156769 | 0.74 | CNR2 (0.42) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL7916999 | 0.73 | NPC1 (0.32) | NPC1RAB9ASMN1; SMN2HSD17B10NFKB1 | |
| SCHEMBL533167 | 0.73 | CLK4 (0.46) | NPC1RAB9ASMN1; SMN2HDAC4NFKB1 | |
| SCHEMBL22130253 | 0.73 | RAB9A (0.68) | NPC1RAB9ASMN1; SMN2HSD17B10HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765054-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-09-19 | — | — | US | claimed |
| US-20140163009-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation (US) | 2014-06-12 | — | — | US | claimed |
| EP-2667709-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2013-12-04 | — | — | EP | claimed |
| WO-2012103008-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2012-08-02 | — | — | WO | claimed |
| CN-102209710-A | Pyrrolidines | PFIZER LTD | 2011-10-05 | — | — | CN | claimed |
| EP-2364296-A1 | PYRROLIDINES | Pfizer Limited (GB) | 2011-09-14 | — | — | EP | claimed |
| WO-2010052625-A1 | PYRROLIDINES | PFIZER LIMITED (GB) | 2010-05-14 | — | — | WO | claimed |
| US-9765054-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| CN-103965099-A | Pyridylaminoacetic Acid Compound | UBE INDUSTRIES | 2014-08-06 | — | — | CN | disclosed |
| CN-101970410-B | Pyridylaminoacetic acid compounds | UBE INDUSTRIES | 2014-06-25 | — | — | CN | disclosed |
| US-20140163009-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| CN-102209710-A | Pyrrolidines | PFIZER LTD | 2011-10-05 | — | — | CN | disclosed |
| EP-2364296-A1 | PYRROLIDINES | Pfizer Limited (GB) | 2011-09-14 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| CN-101970410-A | Pyridylaminoacetic acid compounds | UBE INDUSTRIES | 2011-02-09 | — | — | CN | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010052625-A1 | PYRROLIDINES | PFIZER LIMITED (GB) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163009-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | NPC1 1393/4885RAB9A 4026/4885SMN1; SMN2 3271/4885 |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | NPC1 3585/4885RAB9A 2549/4885SMN1; SMN2 3764/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | NPC1 3814/4885RAB9A 2112/4885SMN1; SMN2 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.